Business Context and Reporting Period
This Form 8-K is filed by ChromaDex Corporation (CDXC) on September 29, 2021, reporting events occurring on September 27, 2021. The filing addresses the conclusion of a jury trial in the "California Action," a long-standing legal dispute between ChromaDex and Elysium Health, Inc., involving former executive Mark Morris.
Key Financial Metrics
This filing does not report standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The primary financial impact disclosed is the expected net recovery from the legal verdict.
- Expected Net Recovery: Approximately $2.25 million to $2.50 million in damages and interest.
- Underlying Dispute Value: The jury found Elysium breached supply agreements regarding approximately $3 million in unpaid ingredients.
Material Changes and Legal Outcome
The jury returned a verdict on September 27, 2021, with the following findings:
- ChromaDex Wins: Elysium breached supply agreements for NIAGEN and pTeroPure by failing to pay for ingredients ordered in June 2016. Mark Morris breached a confidentiality agreement by disclosing company information to Elysium.
- Elysium Wins: The jury ruled in favor of Elysium on counterclaims regarding the breach of a pricing provision in the NIAGEN supply agreement and the fraudulent inducement of a trademark license and royalty agreement.
- Punitive Damages: Elysium was awarded punitive damages on the fraudulent inducement counterclaim.
- Net Result: After offsetting all claims and counterclaims, ChromaDex expects a net payment from Elysium and Mark Morris.
Guidance, Outlook, and Risks
Management Commentary: ChromaDex does not plan to appeal the jury's decision. The company expects to receive the net damages and interest within the stated range of $2.25 million to $2.50 million.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Actual results may differ materially from expectations due to risks and uncertainties discussed in the company's most recent Form 10-K and Form 10-Q. The company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the final judgment amount and payment timeline once the court enters the formal judgment.
- Confirm the specific breakdown of the $2.25 million to $2.50 million net recovery versus the punitive damages awarded to Elysium.
- Review the company's most recent Form 10-K and 10-Q for updated risk factors related to ongoing litigation or supply chain dependencies.
- Monitor future filings for any unexpected appeals or enforcement actions regarding the verdict.